Innate Pharma S.a. sell nvestor
Start price
18.09.21
/
50%
€6.60
Target price
18.09.22
€3.00
Performance (%)
-26.06%
End price
02.10.21
€4.88
Summary
This prediction ended on 02.10.21 with a price of €4.88. The price of Innate Pharma S.a. decreased from the start of the prediction. Compared to the start price this resulted in a performance of -26.06%. nvestor has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Innate Pharma S.a. | - | - | - |
| iShares Core DAX® | -2.196% | -0.532% | 12.492% |
| iShares Nasdaq 100 | -0.074% | 1.843% | 40.598% |
| iShares Nikkei 225® | -2.154% | -1.109% | 22.295% |
| iShares S&P 500 | -0.501% | 1.475% | 28.278% |
According to nvestor what are the pros and cons of Innate Pharma S.a. for the foreseeable future?
Pros
Cons
Lower EBIT Margin than peer group
Bad rating
Increased challenges to pay loans and raise capital
Below average Management
Dependend from some customers or products
Higher risks for its business
Below average Marketposition
Probably not worthwhile Investment
Revenue decline/stagnation expected
EBIT decline/stagnation expected
High valuation
Low dividend yield expected
negative Cash Flow expected
Little Investments for future growth
Risky balance sheet
ROE lower than 10% per year
Bad culture
Little innovation
Few uniques
Growths slower than the competition
Sustainability is little important
high free float
Significant cyclical dependencies
Little known brand
Business model of the past or high risk
Comments by nvestor for this prediction
In the thread Innate Pharma S.a. diskutieren
In the thread Trading Innate Pharma S.a.
Einschätzung wurde nach dem Ende von Catch the Monkey automatisch beendet.
Stopped prediction by nvestor for Innate Pharma S.a.
Innate Pharma S.a.
Start price
Target price
Perf. (%)
€5.00
04.09.21
04.09.21
€2.00
04.09.22
04.09.22
32.00%
18.09.21
18.09.21
Lower EBIT Margin than peer group
Bad rating
Increased challenges to pay loans and raise capital
Below average Management
